Patients with early Parkinson disease who received lixisenatide had a decrease in motor disability progression, but they also experienced gastrointestinal side effects. Lixisenatide vs placebo is ...

An older diabetes treatment called lixisenatide resulted in less progression of motor disability after 12 months in patients in an early stage of the disease Erin Clack is a Staff Editor for PEOPLE.

A recent study published in The New England Journal of Medicine has demonstrated that lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may slow the progression of motor disability in ...

Changes in motor units closely reflect disease severity in people with spinal muscular atrophy (SMA), suggesting potential ...